Looking for a reliable way to lose weight?? Meet Mounjaro UAE, the latest injectable medication that’s making waves among ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

We will focus on telehealth companies, like Jack & Jill, that offer Ozempic alternatives over the counter, such as compounded semaglutide and tirzepatide, as well as top FDA-approved weight loss ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...

Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...

The increase in weight loss with the higher dose was impressive, but still lower than has been achieved in clinical trials of Eli Lilly's rival obesity therapy Zepbound (tirzepatide), which helped ...

For its most recently reported quarter (Q3 of 2024), Hims & Hers generated $401.6 million in revenue. That resulted in a free ...

Lilly is tirzepatide’s patentholder and the manufacturer of the two branded versions of tirzepatide, Mounjaro® (for diabetes) and Zepbound® (for weight loss and, announced on December 20 ...

In addition, this drug can cause nausea or decreased appetite, which can lead to weight loss. Mounjaro contains the active ingredient tirzepatide. (An active ingredient is what makes a drug work.) ...

Eli Lilly started 2024 on a strong note but struggled during the second half of the year. The drugmaker dealt with several ...